Powered By
If you’re living with kidney disease, you may wonder whether semaglutide (Ozempic) or other glucagon-like peptide-1 (GLP-1) medications could help protect your kidneys. These medicines are best known for treating type 2 diabetes and helping with weight loss, but their benefits may go further.
Research on Ozempic and kidney disease has shown promising results. Semaglutide is now approved to lower the risk of worsening kidney disease and kidney injury in adults with both type 2 diabetes and chronic kidney disease (CKD). But could other GLP-1 medications offer similar benefits? Here’s what to know about their benefits and risks.
GLP-1 receptor agonists are medications that work like GLP-1, a hormone your body makes after eating. This hormone helps control blood sugar, digestion, and appetite.
Sign up to view the results!
Continue with Facebook
Continue with Email
GLP-1 medications help your body release insulin when blood sugar is high. They also reduce how much sugar your liver releases, slow how quickly food leaves your stomach, and help you feel full sooner.
These effects can improve blood sugar and promote weight loss, both of which may benefit kidney health. Researchers are also studying whether GLP-1 medications have kidney-protective effects beyond these metabolic improvements.
Clinical trials have found reductions in albuminuria, which is excess albumin protein in the urine and an important marker of kidney damage. Some research also suggests GLP-1 treatment may slow declines in estimated glomerular filtration rate (eGFR), a measure of kidney function.
Semaglutide is sold under several brand names, including Ozempic, Wegovy, and Rybelsus. Although they contain the same drug, their doses and approved uses differ.
Ozempic is available as a once-weekly injection and as tablets. The approval to reduce the risk of worsening kidney disease discussed earlier applies to Ozempic injections, not the tablets.
Other GLP-1 medications include dulaglutide and liraglutide. Tirzepatide is a related medication that acts on two hormones, GLP-1 and glucose-dependent insulinotropic polypeptide.
Although these medications work in similar ways, the evidence for kidney benefits isn’t the same for every drug.
GLP-1 medications may benefit people with CKD in several ways. They can help control blood sugar, which matters because high blood sugar can damage the kidneys.
Many also help with weight loss, and some lower the risk of heart problems, which is especially important because people with CKD have a higher risk of heart disease.
When kidneys are damaged, a protein called albumin can leak into the urine. Studies show that some GLP-1 medications can lower albumin levels, which may be a sign of improved kidney health.
A 2025 analysis found that tirzepatide, a related medication, reduced albumin in the urine of people with type 2 diabetes compared with other treatments or placebo.
However, the researchers found no significant difference in kidney function after about 40 weeks. Lower urine albumin is encouraging, but it doesn’t prove that a medication prevents kidney failure.
Another clinical trial of semaglutide, the SMART study, involved 101 adults without diabetes who had CKD and obesity. The participants were given either a weekly semaglutide injection or a placebo for 24 weeks.
Results showed that semaglutide reduced albuminuria by 52 percent compared with placebo. However, more research is needed to evaluate these effects further.
Kidney impairment doesn’t automatically rule out semaglutide. The current prescribing information states that routine dose adjustment isn’t recommended for renal impairment, including kidney failure, based solely on kidney function.
Monitoring may still be necessary, particularly when gastrointestinal side effects cause fluid loss.
Common semaglutide side effects include nausea, vomiting, diarrhea, stomach pain, and constipation. You may also notice a reduced appetite.
Persistent vomiting or diarrhea can cause dehydration, which may lead to sudden kidney damage, known as acute kidney injury. This risk needs particular attention when starting semaglutide or increasing the dose.
Your healthcare team may check your kidney function if these problems occur. Contact your doctor promptly if you have ongoing vomiting or diarrhea, feel unusually dizzy, or urinate much less than usual.
GLP-1 medications generally have a relatively low risk of causing hypoglycemia (low blood sugar) by themselves. The risk increases when semaglutide is combined with insulin or medications such as sulfonylureas.
A healthcare professional may need to adjust these medications, particularly because CKD itself can increase susceptibility to hypoglycemia.
Semaglutide also carries warnings about pancreatitis (inflammation of the pancreas), gallbladder problems, and complications of diabetic eye disease. It should not be used by people with a personal or family history of medullary thyroid cancer or a rare inherited condition called MEN2.
Your healthcare team can help determine whether a GLP-1 medication is right for you based on your type of kidney disease, other health conditions, and current treatments.
For example, they can help decide how a GLP-1 medication might fit alongside other CKD treatments, such as SGLT2 inhibitors. They can also review your other medications like metformin to see whether any changes or extra monitoring are needed.
Consider asking your healthcare professional:
GLP-1 medications may be one part of managing kidney disease, but they don’t replace other treatments or regular kidney checkups. Although semaglutide has shown kidney benefits in adults with type 2 diabetes and CKD, it hasn’t been proven to help with every type of kidney disease, and other GLP-1 medications may not offer the same benefits.
If you’re considering Ozempic or another GLP-1 medication, talk with your healthcare team about its possible benefits for your condition, whether the research applies to you, the risks to watch for, and how you’ll know whether it’s helping.
Get updates directly to your inbox.
Continue with Facebook
Continue with Email
Continue with Facebook
Continue with Email
Become a member to get even more
Join
Your Privacy Choices
This is a member-feature!
Sign up for free to view article comments.
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.